Holista Colltech’s Collagen Supply Agreement Sets $9M Annual Target by 2028

Strategic Partnership for Advanced Wound Care

Holista Colltech Limited (ASX – HCT) has taken a significant step forward in its pharmaceutical ambitions by entering a binding supply and development agreement with Regenerex Pharma, Inc., a US-based specialist in chronic wound healing solutions. This partnership grants Regenerex exclusive worldwide rights to market Holista’s proprietary ovine collagen products, including patented 300 kDa intact collagen and nano-collagen technologies, specifically for wound care applications.

The initial commercial focus will be the United States, the largest wound care market globally, with plans to expand into other international markets. This move aligns with Holista’s strategic pivot to climb the collagen value chain, moving beyond dietary supplements and food ingredients into high-value medical and pharmaceutical sectors.

Robust Purchase Commitments and Clinical Development

Under the agreement, Regenerex commits to minimum purchase volumes starting at USD 50,000 in 2025, scaling sharply to USD 3 million in 2026, USD 6 million in 2027, and reaching USD 9 million annually from 2028 onwards. This structured escalation provides Holista with a clear revenue growth trajectory tied to Regenerex’s commercialisation efforts.

Regenerex will also lead and fund the clinical trials and regulatory approval processes, including submissions to the US Food and Drug Administration (FDA) and other relevant authorities. This clinical expertise and regulatory pathway are critical for successful market entry and adoption of Holista’s collagen-based wound care products.

Collaborative Innovation and Manufacturing Footprint

Beyond supply, the two companies will collaborate on developing new applications for nano-collagen in advanced wound care, sharing ownership of any resulting intellectual property. This joint innovation effort could unlock further product enhancements and market opportunities.

Manufacturing responsibilities are divided between Holista’s facility in Collie, Western Australia, which will supply ovine collagen stocks, and nano-collagen production in Malaysia, both operating under stringent Good Manufacturing Practice (GMP) and halal certification standards. This diversified manufacturing footprint supports scalability and compliance with international quality requirements.

Leadership Perspective and Market Implications

Holista’s Managing Director, Leong Man Loong, described the agreement as a “major milestone,” highlighting the secured committed partner and the strong growth potential embedded in the deal’s structure. Leveraging Regenerex’s clinical and US market expertise is expected to accelerate Holista’s entry into the global wound care market.

For investors, this deal signals Holista’s transition from a diversified health and wellness company into a focused pharmaceutical collagen supplier with promising growth prospects. However, the ultimate success depends on Regenerex’s clinical trial outcomes and regulatory approvals, which inherently carry uncertainties.